Influenza vaccine composition

Details Influenza vaccine composition Influenza vaccine composition

2008-01-08

2008-01-08

Campell, Bruce R. (Department: 1648)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Virus or component thereof

C424S204100, C424S205100, C424S206100, C424S209100

Reexamination Certificate

active

10480952

ABSTRACT:
An inactivated influenza virus preparation is described which comprises a haemagglutinin antigen stabilized in the absence of thiomersal, or at low levels of thiomersal, wherein the haemagglutinin is detectable by a SRD assay. The influenza virus preparation may comprise a micelle modifying excipient, for example α-tocopherol or a derivative thereof in a sufficient amount to stabilize the haemagglutinin.

REFERENCES:
patent: 5472706 (1995-12-01), Friedman et al.
patent: 5616487 (1997-04-01), Eisfeld et al.
patent: 5919480 (1999-07-01), Yechezkel et al.
patent: 6156297 (2000-12-01), Mellul et al.
patent: 195 47 160 (1997-06-01), None
patent: 0 400 569 (1990-12-01), None
patent: 0 750 907 (1997-01-01), None
patent: 0 985 408 (2000-03-01), None
patent: WO95/11700 (1995-05-01), None
patent: WO98/24409 (1998-06-01), None
patent: WO98/30228 (1998-07-01), None
patent: WO98/42373 (1998-10-01), None
patent: WO98/56414 (1998-10-01), None
patent: WO98/56414 (1998-12-01), None
patent: WO99/11241 (1999-03-01), None
patent: WO99/52549 (1999-10-01), None
patent: WO 01/08495 (2001-02-01), None
patent: WO 01/14411 (2001-03-01), None
patent: WO 01/28552 (2001-04-01), None
patent: WO 02/28426 (2002-04-01), None
MMWR Recomm Rep. Apr. 30, 1999;48(RR-4):1-28 [No authors listed], Table 1 only.
Ball et al, “An assessment of thimerosal use in childhood vaccines”, Pediatrics, vol. 107, No. 5, May 2001 pp. 1147-1154.
Bernard et al., “Autism: A novel of mercury poisioning”, Medical Hypotheses, vol. 56, No. 4, Apr. 2001, pp. 462-471.
Brown et al., “Vaccinator device for delivery propellant-driven aerosols ofStreptococcus suisbacterin into the respiratory tracts of swine”, Vaccine, Butterworth Scientific, Guildford, GB, vol. 15, No. 11, Aug. 1, 1997, pp. 1165-1173.
Ellis, “Technologies for the design, discovery, formulation and administration of vaccines”, Vaccine, Butterworth Scientific, Guildford, GB, vol. 19, No. 17-19, Mar. 21, 2001, pp. 2681-2687.
Goetsch et al., “BBG2Na an RSV subunit vaccine candidate intramuscularly injected to human confers protection against viral challenge after nasal immunication in mice”, Vaccine, Butterworth Scientific Guildford, GB, vol. 19, No. 28-29, Jul. 16, 2001, pp. 4036-4042.
Newman et al., “Use of nonionic block copolymers in vaccines and therapeutics”, Critical Reviews in Therapeutic Drug Carrier Systems, United States 1998, vol. 15, No. 2, 1998, pp. 89-142.
Ott et al., “Enhancement of humoral response against human influenza vaccine with the simple submicron oil/water emulsion adjuvant MF59”, Vaccine, Butterworth Scientific., Guildford, GB, vol. 13, No. 16, Nov. 1, 1995, pp. 1557-1562.
Porschmann et al., “Application of surfactants to the supercritical fluid extraction of nitroaromatic compounds from sediments”, Journal of Chromatography A, Elsevier Science, NL, vol. 816, No. 2, Aug. 14, 1998, pp. 221-232.
Poryvaev et al., “The effect of conditions of storage and composition of viral material on lipid peroxidation of the viral envelope and inactivation of the invluenza virus”,Voprosy virusologii, Russia, vol. 40, pp. 62-65, 1995.

Affiliated with

Also associated with

Rating

Influenza vaccine composition does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Influenza vaccine composition, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Influenza vaccine composition will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3950577